Fig. 3: Overall survival (OS) and progression-free survival (PFS) in patients undergoing deferred ASCT for relapse or consolidation.
From: Deferred autologous stem cell transplantation in systemic AL amyloidosis
a Median OS in patients who underwent deferred ASCT for consolidation was not reached; patients who underwent deferred ASCT for relapse had a median OS of 30 months. b Median PFS in patients who underwent for ASCT for consolidation was not reached; patients who underwent deferred ASCT for relapse had a median PFS of 11 months
